Latigo Biotherapeutics Ups IPO to 19.2 Million Shares
Dow Jones
Aug 07
Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece.
The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between $16 and $18 apiece.
Latigo now expects gross proceeds to be $345.6 million.
Underwriters also have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions.
The company, which develops non-opioid pain medicines, plans to trade on Nasdaq under the symbol LTGO. Trading is set to start Friday, with the offering to close Aug. 10.
It intends to use the proceeds from the offering to advance its clinical pipeline, including its lead product candidate LTG-001.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.